Latest Headlines

Latest Headlines

Forma enlists expert partners to create a portfolio of virtual cancer biotechs

Forma Therapeutics has enlisted some expert assistance through Cancer Research UK's extensive scientific network to drum up a slate of new cancer drug programs in the field of protein homeostasis, with plans to populate a portfolio of virtual companies that can be partnered or sold to its biopharma clientele.

Novartis inks typhoid vax licensing deal with Biological E

When Novartis ($NVS) opened its nonprofit vaccine unit, it gave the team a clear mission--take candidates to proof-of-concept, then license them to manufacturers where the virus is endemic.

GlaxoSmithKline teams with Immunocore on next-gen cancer immunotherapies

It took more than a decade for the executive team at Immunocore to achieve their first Big Pharma partnership for their new approach to developing revved up immunotherapies for cancer. But it's taken just a couple of weeks to add their second big pact.

Report: Academia could better use CROs for early research

More and more, academic researchers are turning to CROs to pitch in on early-stage projects, but schools could better optimize how they use contractors, according to a report in Nature.

Xoma staffers form biotech startup to advance blood pressure med

Xoma has chosen a new home for a fixed-dose combination product for reducing blood pressure, transferring the asset to the startup Symplmed Pharmaceuticals in exchange for equity in the new company and up to double-digit royalties on potential U.S. sales.

Theragenics inks international deal as buyout looms

Theragenics has signed an agreement to get its brachytherapy seeds on the European market, an effort to expand its market share as the company considers a buyout worth up to $71.4 million.

Avanir drops $110M on novel inhaled-delivery migraine device

Avanir Pharmaceuticals is set to pay up to $110 million for an experimental inhaled, dry-powder migraine treatment from PA-based devicemaker OptiNose.

Nonprofit licenses MS mouse model to Biogen Idec to develop new therapies

The nonprofit, Silicon Valley-based Myelin Repair Foundation has licensed its new mouse model for demyelinating diseases like multiple sclerosis to Biogen Idec ($BIIB) for the company's drug discovery programs.

Celgene, others regenerate biotech Tengion's finances with $33.6M

Celgene has invested further in the cash-hungry regenerative medicine specialist Tengion, which tapped the biopharma powerhouse and other backers for a total of $33.6 million to support its two lead programs in early clinical development.

MMS teams up with Datatrak for eClinical heft

MMS Holdings, a CRO focused on regulatory submissions, has signed on with Datatrak to use the company's cloud-based data management platform.